UPDATE: Stifel Downgrades WebMD Health Corp. As Management Presentation Downplays Several Catalysts

In a report published Thursday, Stifel analyst Steven Rubis downgraded the rating on

from Buy to Hold, and removed the $52.00 price target. In the report, Stifel noted, “We are downgrading shares of WebMD from Buy to Hold, as the preponderance of evidence associated with our channel checks reflect negative data trends and deterioration of possible positive catalysts seems to limit share price upside.” WebMD Health Corp. closed on Wednesday at $40.25.